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Background: Despite the popularity of hypnotherapy for smoking cessation, the efficacy of this method is unclear.
We aimed to investigate the efficacy of a single-session of group hypnotherapy for smoking cessation compared to
relaxation in Swiss adult smokers.
Methods: This was a cluster-randomised, parallel-group, controlled trial. A single session of hypnosis or relaxation
for smoking cessation was delivered to groups of smokers (median size = 11). Participants were 223 smokers
consuming ≥ 5 cigarettes per day, willing to quit and not using cessation aids (47.1% females, M = 37.5 years
[SD = 11.8], 86.1% Swiss). Nicotine withdrawal, smoking abstinence self-efficacy, and adverse reactions were assessed
at a 2-week follow-up. The main outcome, self-reported 30-day point prevalence of smoking abstinence, was
assessed at a 6-month follow up. Abstinence was validated through salivary analysis. Secondary outcomes included
number of cigarettes smoked per day, smoking abstinence self-efficacy, and nicotine withdrawal.
Results: At the 6-month follow up, 14.7% in the hypnosis group and 17.8% in the relaxation group were abstinent.
The intervention had no effect on smoking status (p = .73) or on the number of cigarettes smoked per day (p = .56).
Smoking abstinence self-efficacy did not differ between the interventions (p = .14) at the 2-week follow-up, but
non-smokers in the hypnosis group experienced reduced withdrawal (p = .02). Both interventions produced few
adverse reactions (p = .81).
Conclusions: A single session of group hypnotherapy does not appear to be more effective for smoking cessation
than a group relaxation session.
Trial registration: Current Controlled Trials ISRCTN72839675.
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Many smokers would like to give up smoking. Studies
indicate that between 40–80% are willing to quit [1-3].
Up to 80% try to quit smoking without using any assis-
tance [4,5]. However, long-term success with the “cold
turkey method” is low at 7–8% [5,6]. As smokers hold
misperceptions regarding nicotine replacement therapies
(NRT) for smoking cessation, these methods are under-
used [7-11]. For those smokers who are looking for ces-
sation assistance, but who are not motivated to try NRT
or other medications for smoking cessation, a range of* Correspondence: maria.dickson@isgf.uzh.ch
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article, unless otherwise stated.other cessation methods, including hypnotherapy, is avai-
lable. At least one-quarter of smokers who intend to quit
are interested in hypnotherapy [12,13]. There is also re-
markable interest among Swiss smokers [14].
The efficacy of hypnosis as a smoking cessation method
has been investigated [15-26], but there is heterogeneity in
study designs. Several reviews and meta-analyses on hy-
pnotherapy for smoking cessation have been undertaken
[27-31] which, apart from two exceptions [32,33], have
not been able to clearly support the efficacy of hypnothe-
rapy as a smoking cessation method.
In this paper, we report findings from a cluster-
randomised trial that investigates the efficacy of hypno-
therapy for smoking cessation compared to relaxation.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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acterised by a large sample size, comparison is made
with an active control group, and self-reported smoking
abstinence is biologically validated. Our trial therefore
represents a substantial addition to the relatively small
and under-powered body of research on hypnosis for
smoking cessation. We intend to evaluate hypnotherapy
as an affordable, time-saving therapy for smokers with
quit intentions. Therefore, the intervention in our trial is
conducted in a single session, group format.
Methods
Trial design
The protocol for this study has been previously pub-
lished [34]. Regarding the trial design, a divergence be-
tween the protocol and the present article should be
noted. The protocol had announced a simple rando-
mised trial. When recruitment for the study started,
however, we became aware that according to our recruit-
ment procedure, the unit of randomisation was clusters
of individuals rather than individuals. This might result
in participants from a particular cluster having more fea-
tures in common with each other than with participants
from other clusters (e.g. the case of work colleagues at-
tending the therapy session together). Therefore, this
was effectively a cluster-randomised, parallel-group, con-
trolled trial. The clusters refer to the groups of partici-
pants who attended the therapy sessions together. Two
weeks after the intervention, all the participants were
contacted by telephone for a follow-up interview. Six
months after the intervention, another follow-up inter-
view was conducted by telephone.
The relaxation condition was intended to be an active
control group (as opposed to a waiting list control) that
matched the experimental group with regard to therapist
contact time [29]. By choosing this type of control group,
we wanted to evaluate whether hypnotherapy had an ef-
fect in addition to the non-specific effects of therapist
contact, social support and relaxation. We did not include
a waiting list control group as we anticipated that partici-
pants in this kind of control group would not feel any mo-
tivation to quit during the follow-up period, thus biasing
six-month abstinence rates.
Participants
Recruitment was performed through advertisements in
online and print newspapers. Individuals over 18 years
who reported smoking at least five cigarettes a day, not
using any other cessation method at the time of the
study, and intending to quit were eligible to participate.
In contrast to the study protocol, we did not apply
an upper age limit as one older individual (age 78) ful-
filled all other inclusion criteria and we did not antici-
pate any methodological or ethical reasons to excludethis individual. Exclusion criteria were acute alcohol or
substance use other than nicotine and manifest signs of
psychotic symptoms as observed by the therapist at the
start of the therapy sessions.
All interested individuals were mailed information
about the study, in particular regarding inclusion cri-
teria, cost of participation, anonymity, and confiden-
tiality. Further, they were informed that the efficacy of
hypnosis and relaxation in smoking cessation was un-
clear, that there were very low risks associated with these
interventions, and that they would be randomly assigned
to either intervention. The participants were asked not
to use any other smoking cessation aids throughout the
study period. To ensure their commitment to smoking
cessation and study participation, participants paid 40
Swiss Francs (ca. 37 USD) in the course of the therapy
session.
Potential participants were provided with a calendar
showing all possible therapy dates. When a group of
8–15 eligible smokers indicated availability for the same
date, the project leader assigned the group (cluster) to the
next intervention in the sequence.
The therapy sessions took place in the conference
rooms of hotels or the institutions involved, either in
Zurich city or in a small town in Northwest Switzerland
between 8–10 pm on weekdays and between 10–12 am
on Saturdays.
Interventions
The therapy sessions were conducted in Swiss German
language by a 37-year old male hypnosis and relaxation
therapist. The therapy sessions consisted of three parts:
a psycho-educational part (40 minutes), the actual in-
tervention (40 min), and a debriefing (20 min). The con-
tents of each part were recorded in a script which the
therapist was instructed to follow. The psycho-educa-
tional part, which consisted of discussing the benefits of
smoking cessation, was equal in both conditions. In the
second part, the actual intervention took place with
dimmed lights and soft background music. Hypnosis
was induced using guided imagery. Using a calm tone of
voice, the therapist invited the participants to travel
through their body and to progressively feel heavier,
warmer and more comfortable. For example, the par-
ticipants were asked to “feel your toes, heels, ankles,
calves, knees and thighs becoming heavier and heavier”,
to finally “experience the comfortable heaviness of your
whole legs” and then to “sink deeper and deeper into
this state”. This exercise was repeated until the whole
body was covered. The induction of hypnosis required
ten minutes (an extension of five minutes compared
to the protocol) before the first set of suggestions was
made to disconnect pleasant experiences, such as socia-
lising, from the act of smoking. Hypnosis was then
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and by associating (“anchoring”) the resulting state of
deep relaxation with a key word that was subsequently
repeated to maintain this state. During deep relaxation,
the participants were given suggestions targeted at switch-
ing their self-image from that of smokers to non-smokers.
The suggestions contained elements of cognitive-behav-
ioural approaches to hypnotherapy for smoking cessation
[21,35,36]. Suggestions were made for the participants to
use their power to resist smoking in tempting situations
and to deal with symptoms such as mood swings or en-
hanced appetite following smoking cessation. Another set
of suggestions referred to evoking a positive commitment
to smoking cessation, assuming responsibility for the own
body and reducing the physiological and psychological
effects of smoking withdrawal [16,17,24,37]. At the
end of the session, the participants were led back to
full awareness.
In the relaxation condition, the participants were ini-
tially invited to make themselves comfortable and to
relax. No repetitive statements were made, and no an-
chors were used to reinforce and deepen relaxation. The
participants were asked to listen to the music for ten mi-
nutes before the same suggestive sentences as used in
the hypnosis group were given.
All participants were debriefed about the intervention
at the end of the session. The debriefing included infor-
mation on the intervention they had undergone and
responding any open questions from the participants.
Furthermore, the participants received a compact disc
(CD) for use at home that included the contents of the
actual intervention.
To ensure fidelity to the intervention script, the pro-
ject leader performed several random, unannounced
visits to the therapy sessions. There was no indication of
any breach of the script by the therapist.
Outcomes
The primary outcome of this trial was the rate of smo-
king abstinence six months following hypnotherapy,
compared to relaxation. As secondary outcomes, we
compared nicotine withdrawal symptoms in ex-smokers
between the interventions, and we evaluated intervention
differences in self-efficacy and adverse reactions two
weeks after the interventions. Furthermore, we compared
daily cigarette consumption in non-quitters between the
interventions two weeks and six months after the therapy
sessions.
Before the first part of the therapy session, the partici-
pants filled in a range of baseline questionnaires. These
questionnaires assessed sociodemographic information,
nicotine dependence via the Fagerström Test for Nico-
tine Dependence (FTND) [38,39]; smoking history;
smoking abstinence self-efficacy [40,41]; history of othersubstance use; mental health via the Beck Depression
Inventory-V (BDI-V) [42,43], the Beck Anxiety Inven-
tory (BAI) [44,45], and the mental component score
(MCS-12) of the 12-Item Short Form Health Survey
(SF-12) [46,47]; and physical health via body mass index
(BMI) and the physical component score (PCS-12) of the
SF-12 [46,47]. Lifetime diagnoses of anxiety, depression,
lung disease, cancer, and heart disease were assessed [48].
In addition, the participants provided a baseline saliva
sample (Quantisal® saliva collection device, nal von min-
den, Regensburg, Germany). This sample was used to
determine the concentration of cotinine, which is a
metabolite of nicotine, via liquid chromatography-
mass spectrometry/mass spectrometry (LC-MS/MS) ana-
lysis at the Institute of Forensic Medicine of the University
of Zurich.
In the two-week follow-up interview, the seven-day
point prevalence smoking abstinence, frequency of use
of the CD since the therapy session, smoking abstinence
self-efficacy, withdrawal symptoms through the Minnesota
Nicotine Withdrawal scale (MNWS) [49], potential ad-
verse events resulting from the intervention, BAI, and
BDI-V were assessed. The adverse events included com-
mon symptoms that are not typically associated with ni-
cotine withdrawal. These symptoms were assessed on
4-point scales ranging from 1 (not present) to 4 (severe).
At the six-month follow-up interview, the 30-day point
prevalence smoking abstinence, use of the CD in the
previous 30 days, use of other cessation aids, BAI, BDI-V,
and adverse events were investigated. Those participants
who reported smoking abstinence for the previous 30 days
and who had not used other cessation aids were sent a
saliva collection device by post.
Results on the BMI at baseline, the BAI and BDI-V at
both follow-ups, and adverse events at the six-month
follow-up are not reported in the present paper.
Sample size
The cluster-randomized design of this trial required a
recalculation of the sample size compared to the study
protocol [34]. We recalculated sample size on the basis
of group hypnosis studies that did not use nicotine
replacement therapy. In the absence of more recent
investigations we referred to three early trials of group
hypnotherapy and smoking cessation [18,26,50]. Of these,
we used the most conservative result of 25% abstinence
after nine months [18]. That study observed 0% abstin-
ence in the attention-placebo control group. However, we
assumed a rate of cessation without any aids of 7% [6] for
the control group. We aimed for a statistical power of
80% and accepted an alpha level of 5%. In an individual
trial, the target sample size for the current trial would
have been 142 individuals (G*Power, University of Kiel,
Germany). We assumed an ICC of 0.05 and an average
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D = 1 + (10–1) × 0.05 = 1.45 [51]. Therefore, the required
minimum sample size in the present trial was N = 142 ×
1.45 = 206. Our actual sample size was 257.
Implementation
Sequence generation
Assuming an average of 10 individuals per group, the
project leader generated a random sequence of 20 ses-
sions through an online program, with the criterion that
the occurrence of both interventions had to be balanced
(i.e., 10 sessions per intervention). When more partici-
pants signed up for the trial, one last session was ran-
domly allocated by the online program to the hypnosis
intervention.
Ethical approval and informed consent
This cluster-randomised trial was performed in compli-
ance with the Declaration of Helsinki and has been
reviewed by the Ethics Committee of the Canton of
Zurich, which did not declare any objections (KEK-StV-
Nr.16/10). Participants were sent an informed consent
form prior to the therapy session. They were asked to
take the signed form with them to the therapy session.
Blinding
The hypnosis and relaxation therapist was informed via
text message by the project leader after the first part of
the therapy session about which intervention he was
about to perform. The participants remained blind with
regard to their assigned intervention until the end of the
therapy session.
Statistical methods
Chi-square and t-tests were used to compare baseline
characteristics between the hypnosis and the relaxation
group. The data analysis was conducted according to the
intention-to-treat (ITT) principle. In parallel, we ana-
lysed our data on a complete-case basis. When analyses
were performed in a subsample, we re-checked for base-
line differences. The primary outcome was analysed using
logistic regression analysis with “hypnotherapy vs. rela-
xation” as the independent variable, “smoking yes/no”
as the dependent variable, and variables with signifi-
cant baseline differences as covariates. Secondary out-
comes were analysed using linear and ordinal regression
analysis. We did not use generalised estimating equations
(GEE) as originally intended [34] since this procedure was
less suitable to the present outcomes than logistic regres-
sion analysis. STATA 12 SE (College Station, Texas, USA)
was used for the regression analyses. To account for
cluster-randomization, the survey (svy) command was
used in the calculation of all outcomes. This commandaccurately estimates standard errors when the sampling
method is other than simple random sampling.
Results
Flow of the participants
Figure 1 shows the flow of the participants throughout
the trial.
Recruitment
The participants were recruited constantly, starting mid-
April 2011 and ending at the beginning of February
2012. Follow-up interviews took place continuously two
weeks and six months following the therapy dates. Re-
cruitment ended when we reached our intended sample
size.
Data preparation
Data imputation was undertaken in PASW 18.0 (IBM
Corp., Armonk NY) for baseline variables with missing
values. None of these variables had more than 9% miss-
ing values. Data were imputed through the linear regres-
sion method. Scale means for the FTND, self-efficacy,
PCS-12, MCS-12, the MNWS, adverse events, BAI, and
BDI-V were calculated.
Baseline data
Table 1 shows characteristics of the sample. The relax-
ation group was significantly more educated compared
to the hypnosis group which, in turn, showed higher
FTND values and a slightly higher mean on the BAI
than the relaxation group.
Intervention and retention at follow-ups and delay of
follow-ups
We were able to reach 92.2% (n = 107) of participants
from the hypnosis group and 94.4% (n = 101) of partici-
pants from the relaxation group for the first follow-up.
The difference in retention between the groups was not
significant (X2 = 0.41, df = 1, p = .52). For the second
follow-up, we reached 85.3% (n = 99) from the hypnosis
group and 81.3% (n = 87) from the relaxation group;
again, this difference was not significant (X2 = 0.655,
df = 1, p = .42). The difference between the groups re-
garding the delay between the target and the effective
follow-up date was neither significant at the two-week
(t = 0.32, df = 193, p = .75), nor at the six-month
follow-up (t = 1.37, df = 163, p = .17).
Return rate of salivettes and biological validation of
nicotine abstinence
All except one self-reported non-smoker returned the
salivette. The one participant who did not return the
salivette was counted as “smoker”. Biochemical analyses
confirmed the nicotine abstinence, as defined by a value
Randomised therapy sessions (n = 21)
Participants included in baseline 
analyses (n = 116)
Participants included in 2-week 
follow-up analyses 
Complete case protocol (107)
ITT protocol (116)
Participants included in 6-month 
follow-up analyses 
Complete case protocol (99)
ITT protocol (116)
Completed (n = 107)
Lost to follow-up (no response) (7)
Discontinued intervention 
(declined without providing 
reasons) (2)
Median number participants per 
session= 11 (8–15)
Total participants (n= 116)
Excluded (15):
Sickness, emergency (5)
Problems with date (3)
Unexcused absence (7)
Enrolment
Hypnosis sessions (n = 11) Allocation
Baseline
2-Week follow-up  
6-Month follow-up 
Analysis 
Relaxation sessions (n = 10)
Median number of participants 
per session = 11 (7–14)
Total participants (n= 107) 
Excluded (19): 
Sickness, emergency (4)
Problems with date (5)
Unexcused absence (10)
Completed (n = 101)
Lost to follow-up (no response) 
(5)
Discontinued intervention 
(disappointed with received  
intervention) (1)
Completed (n = 87)
Lost to follow-up (no response) 
(18)
Discontinued intervention 
(severe mental problems, 
declined without providing 
reasons) (2)
Completed (n = 99)
Lost to follow-up (no response) 
(17)
Participants included in 
baseline analyses (n = 107)
Participants included in 2-week 
follow-up analyses 
Complete case protocol (101)
ITT protocol (107)
Participants included in 6-
month follow-up analyses
Complete case protocol (87)
ITT protocol (107)
Figure 1 Participant flow through the trial.
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showed slightly higher values than those typically ob-
served in occasional smokers. For our evaluation, these
participants were counted as smokers.
Outcomes and estimation
Primary outcome
At the time of the second follow-up, 17 (14.7%, 95% CI
[0.08, 0.21]) of the participants in the hypnosis group
and 19 (17.8%, 95% CI [0.10, 0.25]) in the relaxation
group reported nicotine abstinence for the previous 30days. The effect of the intervention was not significant
(Table 2). Unadjusted analysis (without controlling for
variables showing baseline group differences) led to a
similar result (OR = 0.80, SE = 0.29, t = −0.62, 95% CI
[0.37, 1.72], p = .54), as well as CC analysis (OR = 0.84,
SE = 0.37, t = −0.40, 95% CI [0.34, 2.09], p = .69).
Secondary outcomes
At the two-week follow-up, 38 (33.3%) of the partici-
pants in the hypnosis group and 26 (24.5%) of those in
the relaxation group reported smoking abstinence in the
Table 1 Baseline characteristics of the hypnosis and the relaxation group and of the total sample
Variable Hypnosis (n = 116) Relaxation (n = 107) Total (N = 223) Test
n % M SD n % M SD n % M SD t, X2
Demographics
Female 52 44.8 53 49.5 105 47.1 0.50
Age 116 38.0 13.2 107 36.9 10.1 223 37.5 11.8 −0.71
Swiss 102 87.9 90 84.1 192 86.1 0.68
Civil status 2.04
Single 49 42.2 51 47.7 100 44.8
Married 45 38.8 43 40.2 88 39.5
Divorced/separated 22 19.0 13 12.1 35 15.7
Education 11.22*
Basic education 13 11.2 4 3.7 17 7.6
Apprenticeship 56 48.3 40 37.4 96 43.0
Maturity 24 20.7 24 22.4 48 21.5
University 23 19.8 39 36.4 62 27.8
Smoking-related variables
FTND 115 5.0 2.2 107 4.4 2.0 222 4.7 2.1 −2.13*
Self-efficacy 115 3.3 0.9 106 3.3 0.8 221 3.3 0.9 −0.43
Cotinine (ng/mL) 115 336.6 119.3 107 326.3 124.6 222 331.6 121.7 −0.63
Age at first cigarette 93 16.2 3.3 85 17.2 3.6 178 16.7 3.5 1.89
Smoking cohabitants 11 24.4 16 38.1 27 31.0 1.89
Cessation attempts
Number 37 3.3 3.4 43 3.7 5.2 80 3.5 4.5 0.37
NRT 38 40.9 34 40.0 72 40.4 0.01
Alternative therapies 18 19.4 16 18.8 34 19.1 0.01
Physical health
PCS-12 116 51.5 6.5 106 52.7 5.6 222 52.1 6.1 −1.56
Lung disease (life) 11 10.1 8 8.2 19 9.2 0.23
Heart disease (life) 6 5.5 3 3.1 9 4.3 0.74
Cancer (life) 4 3.7 1 1.0 5 2.4 1.54
Mental health
MCS-12 116 50.0 8.4 106 50.1 7.5 222 50.1 7.9 −0.10
BDI 116 0.9 0.7 107 0.9 0.7 223 0.9 0.7 −0.95
BAI 116 0.4 0.4 106 0.3 0.3 222 0.4 0.4 −2.23*
Substance consumption
Alcohol (30 days) 116 7.2 6.6 106 8.6 6.7 222 7.9 6.7 1.59
Alcohol (7 days) 116 1.8 1.8 106 2.2 1.6 222 2.0 1.7 1.61
Cannabis (life) 66 56.9 73 68.9 139 62.6 3.39
Cocaine (life) 13 11.2 13 12.3 26 11.7 0.06
Note. M, Mean; SD, Standard deviation.
*p ≤ 0.05. This table was created on the basis of the intention-to-treat dataset.
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not significant (OR = 1.73, SE = 0.60, 95% CI [0.84, 3.57],
t = 1.58, p = .13).
Two weeks after the intervention, the mean number
of cigarettes smoked in the previous seven days wassimilar in both groups (Table 3). Linear regression showed
that the effect of the intervention on the number of
daily cigarettes smoked was not significant (B = .38,
β = .03, SE = .94, t = 0.40, 95% CI [−1.58, 2.33], p = .69,
d = 0.07, 95% CI(d) [−0.26, 0.40], ICC hypnosis = .00,
Table 2 Logistic regression model predicting 30-day point prevalence smoking abstinence at the six-month follow-up
Predictor OR 95% CIs SE t p
Intervention (0 = relaxation, 1 = hypnosis) 0.86 [0.36, 2.06] 0.36 −0.35 .73
FTND 0.89 [0.72, 1.12] 0.09 −1.03 .32
BAI 1.21 [0.45, 3.26] 0.57 0.41 .69
Education
Apprenticeship vs. elementary school 1.20 [0.20, 7.27] 1.03 0.21 .84
Maturity vs. elementary school 2.18 [0.31, 14.96] 2.01 0.85 .41
University vs. elementary school 1.42 [0.24, 8.37] 1.21 0.41 .68
(Constant term) 0.22 [0.0, 1.54] 0.20 −1.62 .12
Note. OR, Odds ratio; CI, Confidence interval; SE, Standard error.
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groups showed higher cigarette consumption compared to
the two-week follow-up (hypnosis M = 13.6, SD = 8.6, re-
laxation M = 14.3, SD = 7.3). The type of intervention did
not significantly predict the number of daily cigarettes
smoked at the six-month follow-up (b = −0.75, β = −0.05,
SE = 1.27, t = −.59, 95% CI [−3.39, 1.89], p = .56,
d = −0.09, 95% CI(d) [−0.42, 0.24], ICC hypnosis = .03,
relaxation = .00).
The hypnosis group members showed a lower MNWS
score than that of the relaxation group members. Linear
regression analysis revealed that the intervention pre-
dicted the MNWS score, although the effect was very
small (B = −.36, β = −.31, SE = .14, t = −2.54, 95% CI
[−0.66, -0.06], p = .02, d = −0.05, 95% CI(d) [−0.58, 0.48],
ICC hypnosis = .00, relaxation = .42). Members of both
intervention groups showed similar self-efficacy (Table 3),Table 3 Means (M) and standard deviations (SD) for
secondary outcomes at the two-week follow-up for the
two intervention groups
Secondary outcome Hypnosis Relaxation
M SD M SD
Daily cigarettes (previous 7 days) 9.40 7.70 8.90 7.00
MNWS 0.60 0.63 0.63 0.55
Smoking abstinence self-efficacy 4.31 0.67 4.22 0.80
Adverse events 1.22 0.30 1.19 0.24
Headaches 1.30 0.61 1.33 0.67
Dry mouth 1.41 0.78 1.32 0.67
Nausea and vomiting 1.06 0.28 1.08 0.34
Taste disorders 1.14 0.40 1.11 0.38
Visual problems 1.19 0.55 1.10 0.39
Abdominal pain 1.23 0.57 1.22 0.52
Constipation 1.30 0.65 1.21 0.52
Skin rash 1.13 0.42 1.11 0.43
Itch 1.18 0.58 1.18 0.48
Abnormal dreams 1.34 0.76 1.26 0.68
Other symptoms 1.13 0.51 1.20 0.61and the intervention type had no effect on self-efficacy
(B = .37, β = .37, SE = .24, t = 1.55, 95% CI [−0.13, 0.86],
p = .14, d = 0.12, 95% CI(d) = [−0.41, 0.65], ICC hyp-
nosis = .33, relaxation = .00).
The adverse event index, as assessed at the two-week
follow-up, showed very similar means for the two inter-
vention groups, and linear regression analyses confirmed
the absence of an intervention effect (B = −.00, β = −.02,
SE = .04, t = −0.24, 95% CI [−0.08, 0.07], p = .81,
d = 0.11, 95% CI(d) [−0.17, 0.39], ICC hypnosis = .01,
relaxation = .00).
Self-reported use of other cessation aids and use of the
CD
Of those participants who were abstinent at the six-
month follow-up, one in the hypnosis group and five in
the relaxation group had used other cessation methods
between the therapy session and the six-month follow-
up. The hypnosis group had used the CD, on average,
1.01 (SD = 4.32) times during the previous 30 days,
and the relaxation group had used it, on average, 0.32
(SD = 1.54) times. This difference was not significant
(t = 1.43, df = 115.86, SE = 0.48, p = .15, 95% CI [0.26, 1.64],
d = 0.21, 95% CI(d) [0.09, 0.50], ICC hypnosis = .00,
relaxation = .00).
Discussion
This is the first study to investigate the efficacy of a sin-
gle session of group hypnosis for smoking cessation in a
large sample of smokers willing to quit. According to
our findings, group hypnosis was not more effective for
smoking cessation than group relaxation.
The abstinence rates resulting from our trial are com-
parable, despite figuring at the lower end, to other stu-
dies of a single session of group hypnosis (18.5-25%
abstinence) [15,18,25]. Two studies reported higher ab-
stinence rates of 45–50% [26,50]. Our abstinence rates
are superior to the previously reported 7–8% success
rate without cessation aids, which might be explained by
our participants’ strong quit intentions [52], experiencing
social support [53-56], having contact with a therapist,
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gestions in a relaxed state.
Both relaxation and hypnosis were associated with few
adverse events two weeks after the intervention, and
there were no group differences. Hypnosis seemed su-
perior to relaxation alone with regard to attenuating
withdrawal symptoms after smoking cessation. Psycho-
logically, hypnosis did not lead to enhanced smoking ab-
stinence self-efficacy compared to relaxation.
Our large sample size supports the generalizability of
our findings to populations with a similar socio-demo-
graphical and cultural background and strong intentions
to quit. On the negative side, generalizability might be
lowered through the fact that in our study, the same
therapist conducted all sessions, which does not allow
quantifying therapist and intervention effects.
Our trial presents some limitations that need to be ad-
dressed. We debriefed our participants about their study
condition because we wanted to prevent them from
speculating about their condition and behaving accord-
ing to their speculation. According to some participants,
they were disappointed not to have received their de-
sired intervention, which could have lowered their mo-
tivation to stay abstinent in the follow-up period. In
retrospect, it would have been more elegant to leave our
participants blinded until the second follow-up, while
assessing their guess regarding their condition and their
expectations of that condition.
The absence of between-group effects could lead to
the idea that the participants in the hypnosis condition
were in no different state compared to the participants
in the relaxation condition. We were not able to check
whether induction of hypnosis was successful as there
was no self-report instrument with sufficient discrimi-
nant validity to differentiate between hypnosis and relax-
ation. Future research should deal with the question of
how easily applicable and economic manipulation checks
in hypnotherapy studies could be conducted.
Conclusions
In conclusion, our study indicates that attending a single
smoking cessation session containing a psycho-
educational part and relaxation in a group of highly mo-
tivated smokers yields success rates of 15–18%. Hypnosis
does not seem to have an effect beyond the non-specific
effects of therapist contact, social support and relaxation
in fostering smoking abstinence.
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